Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials
A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease.
top of page
bottom of page